Shernan G. Holtan

6.9k total citations
176 papers, 3.5k citations indexed

About

Shernan G. Holtan is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Shernan G. Holtan has authored 176 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Hematology, 61 papers in Oncology and 41 papers in Immunology. Recurrent topics in Shernan G. Holtan's work include Hematopoietic Stem Cell Transplantation (87 papers), Acute Myeloid Leukemia Research (29 papers) and Renal Transplantation Outcomes and Treatments (20 papers). Shernan G. Holtan is often cited by papers focused on Hematopoietic Stem Cell Transplantation (87 papers), Acute Myeloid Leukemia Research (29 papers) and Renal Transplantation Outcomes and Treatments (20 papers). Shernan G. Holtan collaborates with scholars based in United States, France and Belgium. Shernan G. Holtan's co-authors include Daniel J. Weisdorf, Svetomir N. Markovic, Douglas J. Creedon, Margaret L. MacMillan, Todd E. DeFor, Bruce R. Blazar, Mukta Arora, Paul Haluska, Claudio G. Brunstein and Wendy K. Nevala and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Shernan G. Holtan

165 papers receiving 3.4k citations

Peers

Countries citing papers authored by Shernan G. Holtan

Since Specialization

Citations

This map shows the geographic impact of Shernan G. Holtan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shernan G. Holtan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shernan G. Holtan more than expected).

Fields of papers citing papers by Shernan G. Holtan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shernan G. Holtan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shernan G. Holtan. The network helps show where Shernan G. Holtan may publish in the future.

Co-authorship network of co-authors of Shernan G. Holtan

This figure shows the co-authorship network connecting the top 25 collaborators of Shernan G. Holtan. A scholar is included among the top collaborators of Shernan G. Holtan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shernan G. Holtan. Shernan G. Holtan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	454 Factors influencing pharmacokinetics of tacrolimus in hematopoietic stem cell transplantation: The integration of microbiome and pharmacogenomics 2025 ·Journal of Clinical and Translational Science ·(unknown), Cheng Shen, Christopher Staley, Shernan G. Holtan	0
2	The Prevalence of Pretransplant Frailty and Mental Distress in Hematopoietic Cell Transplantation and Association with Clinical Outcomes 2024 ·Transplantation and Cellular Therapy ·(unknown), Qing Cao, (unknown), Fiona He, Angela Krämer, Shernan G. Holtan, Mark Juckett, (unknown), Mukta Arora, Joseph Maakaron, Daniel J. Weisdorf, Najla El Jurdi	1
3	Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes 2024 ·Transplantation and Cellular Therapy ·(unknown), Ryan Shanley, Shernan G. Holtan, Margaret L. MacMillan, Daniel J. Weisdorf, Najla El Jurdi	1
4	Treatment-Sensitive and Treatment-Dependent Chronic Graft-versus-Host Disease Yield Superior Failure-Free and Overall Survival Compared to Treatment-Resistant Chronic Graft-versus-Host Disease 2024 ·Transplantation and Cellular Therapy ·Najla El Jurdi, (unknown), Ryan Shanley, Shernan G. Holtan, Margaret L. MacMillan, Daniel J. Weisdorf	0
5	Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis 2024 ·Cancer Research Communications ·Armin Rashidi, (unknown), Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, (unknown), Mohammad H. Khan, (unknown), Qing Cao, Xianghua Luo, Amanda J. Kabage, (unknown), Sivapriya Ramamoorthy, Shernan G. Holtan, Daniel J. Weisdorf, Alexander Khoruts, Christopher Staley	8
6	Allogeneic Hematopoietic Cell Transplant For Bone Marrow Failure or Myelodysplastic Syndrome in Dyskeratosis Congenita/Telomere Biology Disorders: Single-Center, Single-Arm, Open-Label Trial of Reduced-Intensity Conditioning Without Radiation 2024 ·Transplantation and Cellular Therapy ·(unknown), (unknown), Qing Cao, (unknown), Gregory M. Vercellotti, Shernan G. Holtan, (unknown), (unknown), Stephanie A. Terezakis, Jakub Tolar, Christen L. Ebens	0
7	Graft-versus-host disease: teaching old drugs new tricks at less cost 2023 ·Frontiers in Immunology ·(unknown), Shernan G. Holtan	5
8	JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results 2023 ·Blood ·Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco L. Davila, Claudio Anasetti, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller, Veronika Bachanová, (unknown), Brian C. Betts	1
9	Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial 2023 ·Clinical Cancer Research ·Armin Rashidi, (unknown), Tauseef Ur Rehman, Heba Elhusseini, David Kazadi, (unknown), Mohammad H. Khan, (unknown), Qing Cao, Xianghua Luo, Amanda J. Kabage, (unknown), Shernan G. Holtan, Daniel J. Weisdorf, Alexander Khoruts, Christopher Staley	25
10	A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement 2023 ·Bone Marrow Transplantation ·Rohtesh S. Mehta, Haris Ali, (unknown), (unknown), (unknown), Voravit Ratanatharathorn, Saar Gill, Gèrard Socié, Kevin Anderson, J Cahn, (unknown), Richard E. Champlin, Elizabeth J. Shpall, Shernan G. Holtan, Amin M. Alousi	5
11	Chronic GVHD after steroid-sensitive, -dependent, and -refractory acute GVHD: incidence and clinical outcomes 2023 ·Blood Advances ·(unknown), Daniel J. Weisdorf, Ryan Shanley, Ahmad Rayes, Shernan G. Holtan, Jo‐Anne H. Young, Margaret L. MacMillan, Najla El Jurdi	5
12	Sarcopenia Predicts Inferior Progression Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·(unknown), Qing Cao, Mark Juckett, Brian C. Betts, Shernan G. Holtan, Najla El Jurdi, Marie Hu, Veronika Bachanová, Mukta Arora, Joseph Maakaron	0
13	High cutaneous amphiregulin expression predicts fatal acute graft‐versus‐host disease 2022 ·Journal of Cutaneous Pathology ·(unknown), Daniel D. Miller, Todd E. DeFor, Bruce R. Blazar, Angela Panoskaltsis‐Mortari, Brian C. Betts, Margaret L. MacMillan, Daniel J. Weisdorf, Shernan G. Holtan	3
14	Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements 2022 ·Gut Microbes ·Mohammad H. Khan, (unknown), Armin Rashidi, Shernan G. Holtan, Alexander Khoruts, Ajay K. Israni, Pamala A. Jacobson, Christopher Staley	11
15	Protective Effect of Intestinal Blautia Against Neutropenic Fever in Allogeneic Transplant Recipients 2022 ·Clinical Infectious Diseases ·Armin Rashidi, Jonathan U. Peled, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, (unknown), (unknown), Thomas Kaiser, Shernan G. Holtan, Alexander Khoruts, Daniel J. Weisdorf, Christopher Staley	8
16	Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results 2021 ·Clinical Cancer Research ·Joseph Pidala, Kelly Walton, Hany Elmariah, Jongphil Kim, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco L. Davila, Michael L. Nieder, Elizabeth M. Sagatys, Shernan G. Holtan, Nicholas J. Lawrence, Harshani R. Lawrence, Bruce R. Blazar, Claudio Anasetti, Saı̈d M. Sebti, Brian C. Betts	15
17	Gut microbiota response to antibiotics is personalized and depends on baseline microbiota 2021 ·Microbiome ·Armin Rashidi, Maryam Ebadi, Tauseef Ur Rehman, Heba Elhusseini, (unknown), Thomas Kaiser, Shernan G. Holtan, Alexander Khoruts, Daniel J. Weisdorf, Christopher Staley	45
18	Vancomycin-resistance gene cluster, vanC, in the gut microbiome of acute leukemia patients undergoing intensive chemotherapy 2019 ·PLoS ONE ·Armin Rashidi, Zhigang Zhu, Thomas Kaiser, Dawn A. Manias, Shernan G. Holtan, Tauseef Ur Rehman, Daniel J. Weisdorf, Alexander Khoruts, Gary M. Dunny, Christopher Staley	8
19	Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors 2018 ·Clinical Cancer Research ·Kim Margolin, Chihiro Morishima, Vamsidhar Velcheti, Jeffrey S. Miller, Sylvia M. Lee, Ann W. Silk, Shernan G. Holtan, Andreanne M. Lacroix, Steven P. Fling, Judith C. Kaiser, Jack O. Egan, Monica Jones, Peter R. Rhode, Amy D. Rock, Martin A. Cheever, Hing C. Wong, Marc S. Ernstoff	146
20	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up 2018 ·Biology of Blood and Marrow Transplantation ·Erica D. Warlick, Todd E. DeFor, Nelli Bejanyan, Shernan G. Holtan, Margaret L. MacMillan, Bruce R. Blazar, Kathryn E. Dusenbery, Mukta Arora, Veronika Bachanová, Sarah Cooley, Aleksandr Lazaryan, Philip B. McGlave, Jeffrey S. Miller, Armin Rashidi, Arne Slungaard, Gregory M. Vercellotti, Celalettin Üstün, (unknown), Daniel J. Weisdorf	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact